Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Host Response and Inflammation

Severity of Group B Streptococcal Arthritis in Selected Strains of Laboratory Mice

Manuela Puliti, Francesco Bistoni, Christina von Hunolstein, Graziella Orefici, Luciana Tissi
Manuela Puliti
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, 06122 Perugia, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Bistoni
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, 06122 Perugia, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina von Hunolstein
Laboratory of Bacteriology and Medical Micology, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graziella Orefici
Laboratory of Bacteriology and Medical Micology, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luciana Tissi
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, 06122 Perugia, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.69.1.551-555.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The susceptibilities of C3H/HeN, BALB/c, and C57BL/6N mouse strains to group B streptococci (GBS) infection were evaluated. C3H/HeN mice developed severe polyarthitis; mild lesions and no lesions were observed in BALB/c and C57BL/6N mice, respectively. A correlation between the severity of arthritis, the number of GBS in the joints, and local interleukin-6 and interleukin-1β production was evident.

Group B streptococci (GBS) are a leading cause of life-threatening infection in neonates and young infants (1), and invasive infections caused by GBS have been increasingly recognized in adult populations (2-4). Different susceptibilities to GBS infections among the races have been shown, with the prevalence of GBS colonization during pregnancy greatest in Hispanics of Caribbean origin, followed by, in descending order for prevalence, blacks, whites, and other Hispanics (predominantly Mexicans) (5, 7). More recently, it has been reported that GBS disease rates for infants born to black, Hispanic, and Asian mothers are higher than those for infants born to white mothers (17). Similar differences in susceptibility to GBS infection have also been observed in adults (3).

Septic arthritis has been described as a clinical manifestation of late-onset GBS infection in neonates (1). In adults, GBS arthritis is often associated with advanced age and other risk factors, including cancer, diabetes mellitus, cardiovascular disease, chronic renal insufficiency, alcoholism, human immunodeficiency virus infection, neurological disease, and cirrhosis (8-12).

A previous study described an experimental mouse model of type IV GBS systemic infection with clinical features that closely resemble those of infection in humans, in particular, the appearance of multifocal septic arthritis (14).

The aim of this study was to ascertain whether the genetic disparity among different mouse strains influenced the response to GBS infection. In particular, the appearance and severity of arthritis and the cytokine profile during infection were monitored for each mouse strain.

Inbred BALB/c (H-2d), C57BL/6N (H-2b) and C3H/HeN (H-2k) mice, 8 weeks old, were obtained from Charles River Breeding Laboratories (Calco, Milan, Italy).

Type IV GBS reference strain GBS 1/82 (GBS IV) was used throughout the study. Microorganisms were grown overnight at 37°C in Todd-Hewitt broth (Oxoid Ltd., Basingstoke, Hampshire, England). The bacterial suspension for experimental infection was prepared in RPMI 1640 medium (GIBCO, Life Technologies, Milan, Italy) as previously described (14). Mice were inoculated intravenously via the tail vein with 1 × 107 or 5 × 107 GBS IV CFU/mouse in a volume of 0.5 ml. Control mice were injected in the same way with 0.5 ml of RPMI 1640 medium. Ten animals per mouse strain were used in each experimental group. Mortality was recorded at 24-h intervals for 30 days. Mice were examined daily by two independent observers for 2 months to evaluate joint inflammation. Arthritis was defined as visible erythema or swelling of at least one joint. To evaluate the intensity of arthritis, clinical scoring (arthritic index) was used for each limb, with points assigned as follows (maximum score, 12 points): 0, normal; 1 point, mild swelling and erythema; 2 points, moderate swelling and erythema; 3 points, marked swelling, erythema, and/or ankylosis. The arthritic index was constructed by dividing the total score by the number of animals used in each experimental group. To confirm clinical signs of arthritis, histological studies were performed as previously described (14). Joints were examined for the presence of articular damage. Blood and joint infections in mice infected with 107 GBS IV CFU were determined by CFU evaluation as previously described (14). Blood and articular samples from mice injected with 107 GBS IV CFU and from uninfected controls were obtained as previously described (15), and interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor necrosis factor alpha concentrations were measured with commercial enzyme-linked immunosorbence assay kits (Amersham Pharmacia Biotech Ltd, Amersham, United Kingdom) according to the manufacturer's instructions.

Upon injection with 1 × 107 GBS IV CFU/mouse, no mortality was observed in C57BL/6N mice, while 40% of C3H/HeN and 30% of BALB/c mice died (Fig. 1A). C3H/HeN mice developed severe arthritis (mean arthritic index ± standard deviation, 3.9 ± 0.2); 90% of the animals had articular lesions on day 10 after infection, whereas only 10% of BALB/c mice developed mild arthritis (Fig. 1B and C). No articular lesions were evident in C57BL/6N mice. With an inoculum size of 5 × 107 GBS IV CFU/mouse, mortality increased to 100% in C3H/HeN and in BALB/c mice, while only 20% of C57BL/6N mice died (data not shown). Using the increased inoculum size, 30% of BALB/c mice developed arthritis, while none of the C57BL/6N mice manifested any clinical sign of arthritis (data not shown). Quantitative monitoring of bacteremia and GBS growth in the joints, after injection of 1 × 107 GBS CFU/mouse, showed that the number of CFU was always higher in C3H/HeN mice than in C57BL/6N or BALB/c mice (Fig.2); the lowest rate of GBS growth in the joints was observed in C57BL/6N mice.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Survival (A), incidence (B), and severity (C) of arthritis in C3H/HeN (■), C57BL/6N (●), and BALB/c (▴) mice injected with 1 × 107 CFU of GBS IV per mouse. The data for panel A are the cumulative results of three separate experiments, each performed with 10 animals per mouse strain. For panels B and C, the values are the means ± standard deviations of three separate experiments, each performed with 10 animals per mouse strain. P values of ≥0.001 have been omitted. ∗,P < 0.001 (C3H/HeN versus C57BL/6N and BALB/c mice) according to χ2 test. •, P < 0.001 (C3H/HeN versus C57BL/6N and BALB/c mice) according to Student'st test.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Bacterial growth in joints and blood of C3H/HeN (■), C57BL/6N (●), and BALB/c (▴) mice infected with 1 × 107 CFU of GBS IV per mouse. The data are the means ± standard deviations of three separate experiments. Three mice per strain were sacrificed at each time point. The results are expressed as the number of CFU per ml of blood or per ml of joint homogenate.P values of ≥0.001 have been omitted. ∗,P < 0.001 (C3H/HeN versus C57BL/6N and BALB/c mice) according to Student's t test.

Great differences in systemic and local cytokine production were evident among the mouse strains after injection of 1 × 107 GBS CFU/mouse (Fig. 3). IL-1β reached detectable levels in the sera of each strain, with a maximal value on day 5 after infection; the highest concentration was detected in C3H/HeN mice (P < 0.001). No IL-1β production was observed in the joints of C57BL/6N or BALB/c mice, while in C3H/HeN mice the IL-1β joint concentration began to increase 5 days after GBS injection and reached a value of about 500 pg/ml on day 10. High levels of IL-6 were detected in the sera of all mouse strains, with peak values on day 1 after infection, followed by a progressive decrease. As for IL-1β, the highest IL-6 production was observed in the sera of C3H/HeN mice. Moreover, the IL-6 concentration progressively increased from day 1 to day 10 in the joints of these mice, while in the joints of C57BL/6N and BALB/c mice IL-6 levels never exceeded a value of 50 pg/ml. No tumor necrosis factor alpha production was evident in the sera and joints of any mouse strain (data not shown). The high severity of arthritis in C3H/HeN mice was confirmed by histopathological studies, showing articular cavities filled with purulent exudate 1 week after infection and joint destruction within 20 days (data not shown). There was much less inflammatory involvement in the joints of BALB/c mice, and no signs of inflammation were observed in C57BL/6N mice (data not shown).

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Kinetics of appearance and cytokine concentrations in sera and joints of C3H/HeN (■), C57BL/6N (●), and BALB/c (▴) mice infected with 1 × 107 CFU of GBS IV per mouse. The data are the means ± standard deviations of three separate experiments. Three mice per strain were sacrificed at each time point.P values of ≥0.001 have been omitted. ∗,P < 0.001 (C3H/HeN versus C57BL/6N and BALB/c mice); •, P < 0.001 (C3H/HeN versus C57BL/6N mice); †,P < 0.001 (BALB/c versus C57BL/6N mice) according to Student's t test.

The laboratory mouse offers outstanding potential as a model for GBS arthritis. Septic arthritis observed in late-onset GBS disease is hematogenously acquired, and the more frequently affected joints are hip, ankle, and wrist (1). In our murine model, bacteremia is present for more than 10 days after GBS infection, and the localization of articular lesions is similar to that observed in humans (13). In this study, various genotypes appeared to be differently susceptible to GBS infection. The appearance of arthritis is undoubtedly the by-product of a multifactorial process. As previously reported (14, 16), the number of microorganisms that reach the joints is a determinant for the establishment of permanent arthritis. BALB/c and particularly C57BL/6N mice appeared to efficiently control GBS levels at this site, thus accounting for the appearance of only mild articular lesions (or the complete absence of such lesions) in these two strains. On the contrary, the severe arthritis induced by GBS IV in C3H/HeN mice correlated with the high number of bacteria recovered from the joints. Recent evidence that proinflammatory cytokines, such as IL-6 and IL-1β, may participate in the pathogenesis of GBS disease (14) is confirmed by the present study. In fact, the highest concentrations of these cytokines in the sera and joints of C3H/HeN mice correlated with the highest mortality and the most severe articular lesions. It is worth noting that BALB/c mice, although showing mild arthritis, had a mortality rate similar to that of C3H/HeN mice. IL-1β and IL-6 serum levels in these mice appeared to account for their respective susceptibility to GBS infection.

In conclusion, our results indicate that experimental infection of different strains of inbred mice with GBS IV results in articular lesions whose severity appears to be based on a genetically determined host immune response which controls the bacterial burden and inflammatory response. A better understanding of the host factors that influence the different resistance to arthritis of mice infected with GBS may have implications for humans.

ACKNOWLEDGMENTS

We thank Eileen Mahoney Zannetti for dedicated editorial assistance.

This study was supported by M.U.R.S.T. (1997/1998 “Infections in the immunocompromised host: modulation of the immune response”), Rome, Italy.

Notes

Editor: A. D. O'Brien

FOOTNOTES

    • Received 24 July 2000.
    • Returned for modification 19 September 2000.
    • Accepted 5 October 2000.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Baker C. J.,
    2. Edwards M. S.
    Group B streptococcal infections Infectious diseases of the fetus and newborn infant 4th ed. Remington J. S., Klein J. O. 1995 980 1054 W. B. Saunders Philadelphia, Pa
  2. 2.↵
    1. Cooper B. W.,
    2. Morganelli E.
    Group B streptococcal bacteremia in adults at Hartford Hospital 1991–1996.Conn. Med.621998515517
    OpenUrlPubMed
  3. 3.↵
    1. Farley M. M.,
    2. Harvey R. C.,
    3. Stull T.,
    4. Smith J. D.,
    5. Schuchat A.,
    6. Wenger J. D.,
    7. Stephens D.
    A population-based assessment of invasive disease due to group B Streptococcus in non-pregnant women.N. Engl. J. Med.328199318071811
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Gardam M. A.,
    2. Low D. E.,
    3. Saginur R.,
    4. Miller M. A.
    Group B streptococcal necrotizing fascitis and streptococcal toxic shock-like syndrome in adults.Arch. Intern. Med.158199817041708
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Hickman M. E.,
    2. Rench M. A.,
    3. Ferrieri P.,
    4. Baker C. J.
    Changing epidemiology of group B streptococcal colonization.Pediatrics1041999203209
    OpenUrlAbstract/FREE Full Text
  6. 6.
    1. Jackson L. A.,
    2. Hilsdon R.,
    3. Farley M. M.,
    4. Harrison H.,
    5. Reingold A. L.,
    6. Plikaytis B. D.,
    7. Wenger D.,
    8. Schuchat A.
    Risk factors for group B streptococcal disease in adults.Ann. Intern. Med.1231995415420
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Regan J. A.,
    2. Klebanoff M. A.,
    3. Nugent R. P.
    The epidemiology of group B streptococcal colonization in pregnancy. Vaginal infections and prematurity study.Obstet. Gynecol.771991604610
    OpenUrlPubMedWeb of Science
  8. 8.↵
    1. Schattner A.,
    2. Vosti K. L.
    Bacterial arthritis due to beta-hemolytic streptococci of serogroups A, B, C, F, and G. Analysis of 23 cases and a review for literature.Medicine771998122139
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Schattner A.,
    2. Vosti K. L.
    Recurrent group B streptococcal arthritis.Clin. Rheumatol.171998387389
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Schwartz B.,
    2. Schuchat A.,
    3. Oxtoby M. J.,
    4. Cochi S. I.,
    5. Hightower A.,
    6. Broome C. V.
    Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta.JAMA266199111121114
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Small C. B.,
    2. Slater L. N.,
    3. Lowy F. D.,
    4. Small R. D.,
    5. Salvati E. A.,
    6. Casey J. I.
    Group B streptococcal arthritis in adults.Am. J. Med.761984367375
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Strauss C.,
    2. Kaplan D.,
    3. Bergemer A. M.,
    4. le Parc J. M.
    Destructive polyarthritis due to a group B streptococcus.Rev. Rhum. Engl. Ed.641997339341
    OpenUrlPubMed
  13. 13.↵
    1. Tissi L.
    Experimental group B Streptococcus arthritis in mice Handbook of animal models of infection Zak O., Sande M. 1999 549 559 Academic Press London, United Kingdom
  14. 14.↵
    1. Tissi L.,
    2. Marconi P.,
    3. Mosci P.,
    4. Merletti L.,
    5. Cornacchione P.,
    6. Rosati E.,
    7. Recchia S.,
    8. von Hunolstein C.,
    9. Orefici G.
    Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis.Infect. Immun.58199030933100
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Tissi L.,
    2. Puliti M.,
    3. Barluzzi R.,
    4. Orefici G.,
    5. von Hunolstein C.,
    6. Bistoni F.
    Role of tumor necrosis factor alpha, interleukin-1β, and interleukin-6 in a mouse model of group B streptococcal arthritis.Infect. Immun.67199945454550
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Tissi L.,
    2. von Hunolstein C.,
    3. Bistoni F.,
    4. Marangi M.,
    5. Parisi L.,
    6. Orefici G.
    Role of group B streptococcal capsular polysaccharides in the induction of septic arthritis.J. Med. Microbiol.471998717723
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Zaleznik D. F.,
    2. Rench M. A.,
    3. Hillier S.,
    4. Krohn M. A.,
    5. Platt R.,
    6. Lee M.-L. T.,
    7. Flores A. E.,
    8. Ferrieri P.,
    9. Baker C. J.
    Invasive disease due to group B streptococcus in pregnant women and neonates from diverse population groups.Clin. Infect. Dis.302000276281
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Severity of Group B Streptococcal Arthritis in Selected Strains of Laboratory Mice
Manuela Puliti, Francesco Bistoni, Christina von Hunolstein, Graziella Orefici, Luciana Tissi
Infection and Immunity Jan 2001, 69 (1) 551-555; DOI: 10.1128/IAI.69.1.551-555.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Severity of Group B Streptococcal Arthritis in Selected Strains of Laboratory Mice
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Severity of Group B Streptococcal Arthritis in Selected Strains of Laboratory Mice
Manuela Puliti, Francesco Bistoni, Christina von Hunolstein, Graziella Orefici, Luciana Tissi
Infection and Immunity Jan 2001, 69 (1) 551-555; DOI: 10.1128/IAI.69.1.551-555.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • Notes
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Arthritis, Infectious
Streptococcal Infections
Streptococcus agalactiae

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522